METASTATIC CANCER

This early-stage study tests a radioactive imaging agent called Y-NM600 in people with metastatic cancer who are already taking immunotherapy drugs (anti-PD-1 or anti-PD-L1). The goal is to find a safe dose and see if the agent can help the drugs work better. Up to 60 participant…

This early-stage study tests whether combining a focused ultrasound treatment (histotripsy) with standard immunotherapy drugs (ipilimumab and nivolumab) is safe and tolerable for people with advanced cancer that has not responded to other treatments. About 24 adults with metastat…

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This study is the first time IDRX-42 is being tested in people. It is for adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tum…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug works by blocking a protein (CD73) that tumors use to hide from the immune system. The study first finds the safest dose of IPH5301 alone, then tests it combined…

This early-phase study tests whether adding precise radiation to up to 10 tumor spots can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread to 3-10 places. About 28 adults will receive the combination and be monitored for changes in …

This early-stage study tests a new method to both detect and treat metastatic cancers (cancers that have spread). The approach uses a special molecule that targets a protein found on many cancer cells. First, a radioactive imaging agent helps locate tumors. Then, a therapeutic ra…

This early-phase trial tests an experimental drug called ALTA2618 in about 110 adults whose advanced solid tumors (including breast and endometrial cancers) have a specific AKT1 E17K gene mutation. The main goals are to check the drug's safety and find the right dose. Participant…

This study tests whether combining two drugs, cabozantinib and nivolumab, can slow the growth of advanced prostate cancer that has stopped responding to hormone therapy. About 47 men with metastatic castration-resistant prostate cancer will receive the combination. The main goal …

This study tests a new immunotherapy for people with advanced HPV-related cancers (cervical, throat, anal, and others). Participants receive specially engineered immune cells designed to attack HPV-infected tumor cells, along with chemotherapy and a drug to boost cell activity. T…

This study tests a radiation treatment (Y90) to help grow the liver in people with liver cancer who need surgery but don't have enough healthy liver left. The goal is to make surgery possible and improve survival. About 104 participants will receive either standard or optimized Y…

This study tests an experimental pill called INX-315 in 150 people with advanced cancers, including certain breast and ovarian cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study has three…

This study tests whether adding the drug azeliragon to targeted radiation therapy can safely shrink brain tumors and keep them under control longer. About 46 adults with cancer that has spread to the brain will receive the combination. The goal is to improve tumor response and de…

This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for si…

This study tests a drug called MGD019 to see if it can help control advanced cervical cancer in people who haven't had treatment yet. About 40 adults with cancer that has spread or come back will receive the drug. The main goal is to see if it helps them live longer.

This study tests whether precise, high-dose radiation (stereotactic radiotherapy) can restore the effectiveness of immunotherapy in people with metastatic solid tumors whose cancer had been controlled for at least 6 months but then started growing again. About 35 participants wil…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs like gemcitabine or irinotecan. About 442 participants wi…

This study tests a new way to treat liver metastases by combining a drug called bevacizumab with a procedure called TACE, which delivers chemotherapy directly to the liver. The goal is to see if this combination helps patients live longer and shrinks tumors better than TACE alone…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors, including stomach, pancreatic, and bile duct cancers. The main goals are to check the drug's safety, find the best dose, and see how the body process…

This study tests a new drug called AU-007 in people with advanced solid tumors (like melanoma or lung cancer) that cannot be removed by surgery or have spread. The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007…

This study gives people with advanced or metastatic cancer continued access to experimental drugs they are already benefiting from in earlier studies. The main goal is to monitor long-term safety, including side effects. About 50 participants will join this Phase 3 rollover study…

This early-phase study tests a new treatment called PTC13, which uses a patient's own immune cells (T cells) engineered to target a protein called CEA found on certain cancer cells. The goal is to see if it is safe and tolerable for people with advanced solid tumors like colorect…

This early-phase study tests a new drug called JZP815 in adults with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to find a safe dose and see if the drug can shrink tumors. About 332 participants who have tried all other tr…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study tests a new treatment called 177Lu-SN201 for people with advanced solid tumors that have not responded to standard therapies. The treatment uses tiny particles that deliver radiation directly to tumors. The goal is to find the safest dose and see if it can shrink tumor…

This study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…

This early-stage trial tests a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that have a marker called NY-ESO-1. The study includes people with advanced cancers like sarcoma, melanoma, breast, lung, bladder, and ova…

This study looks at whether two common immunotherapy drugs, nivolumab and pembrolizumab, can be given less frequently than the current standard schedule. Researchers will measure drug levels in the blood of 264 adults with advanced or metastatic cancer to see if extended interval…

This phase 3 study compares a new two-drug immunotherapy (botensilimab + balstilimab) against the current standard treatment (chemotherapy plus nivolumab) in people with advanced or metastatic stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal…

This study tests whether giving high-precision radiation (SABR) to every visible tumor can help people with 11 or more metastases live longer. About 138 adults with metastatic cancer will be randomly assigned to either standard care or SABR to all disease sites. The goal is to se…

This study is for people with metastatic cancer that has spread and who have a specific gene change called an ATM mutation. Researchers want to see if a lower dose of radiation can still control the tumor, which might mean fewer side effects. About 40 adults will take part, and t…

This is the first study in people testing a new antibody drug called NTX-1088, which targets a protein found on many cancer cells. The trial will test the safety of NTX-1088 given alone and in combination with an existing immunotherapy drug (pembrolizumab) in 90 patients with adv…

This early-stage study tests a new PET imaging agent, 18F-Clofarabine, to measure an enzyme (DCK) activity in metastatic cancers. The goal is to see if this scan can predict whether drugs like gemcitabine will be taken up by cancer cells. About 4 adults with metastatic cancer wil…

This study tests a new radioactive tracer called FAP-2286 to see if it can better detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure how safe the tracer is and how well it high…

This early study tests whether a special radioactive tracer called [68Ga]Ga-ABY-025 can improve PET scans to find HER2-positive tumors in people with advanced breast, stomach, head and neck, or esophageal cancers. About 30 adults already receiving standard HER2-targeted therapy w…

This early-phase study tests a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and cancer that has spread. About 30 adults with suspected cancer will receive the tracer and then be scanned. Rese…

This study tests two programs to help parents with advanced cancer communicate better with their children aged 10 to 25. One program provides education, while the other adds hands-on practice. The goal is to improve how often and how well families talk about the illness, reducing…

This study tests a special type of proton radiation called GRID for people with large or previously treated tumors that cannot be removed. The goal is to safely relieve symptoms like pain. About 24 adults will receive three radiation sessions. Researchers will check for side effe…

This study tests a new type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better and with fewer side effects than standard radiation. About 37 adults with advanced solid tumors will receive this treatme…

This study tests the ApricityCare program, which helps doctors spot early signs of side effects from cancer treatments and treat them quickly. The goal is to prevent side effects from getting worse and reduce the number of patients who have to stop their cancer therapy. About 425…

This study looks at whether special scans and blood tests can help doctors know if endocrine therapy is working in people with a certain type of advanced breast cancer (lobular breast cancer). About 8 participants will get a PET scan and give blood samples before and after 4 week…

This study compares a newer MRI-based scan (DWI) with the standard FDG PET scan to see how well each finds cancer spread in people with metastatic cancer. About 30 adults with cancer that has spread will get both scans, and researchers will compare the results. The goal is to see…

This study looks at how much of the drug T-DXd gets into brain tumors after being injected into the body. It includes 30 adults with brain cancer that has the HER2 protein. Researchers will measure drug levels in the tumor during surgery to see if it could be a useful treatment.

This study is a registry that collects medical information and patient feedback from 2,000 adults with metastatic cancer who are receiving radiation therapy as part of their standard care. The goal is to build a large dataset to help researchers understand how radiation affects o…

This study is testing whether a special smart shirt (Hexoskin) can help monitor and detect side effects early in 100 patients receiving palliative radiotherapy for metastatic cancer. Participants will wear the shirt and use a mobile app to track their health. The goal is to see i…

This study tests a simple scoring system that uses lab results, emergency room visits, and cancer type to predict if someone with metastatic cancer will survive at least 30 days after starting palliative radiation therapy. About 214 adults with advanced cancer will be enrolled. T…

This study looks at whether asking people with advanced or metastatic cancer about their financial worries every month can improve their quality of life and reduce stress. About 1,000 adults who are getting cancer treatment that is not meant to cure them will take part. The goal …

This study is a registry that collects information from 300 adults with cancer that has spread to other parts of the body (metastatic cancer). The goal is to track short-term side effects of a precise, high-dose type of radiation called ablative radiotherapy. No new treatment is …